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A
b
stract 
This
 paper describes
 a softw
are process
 im
prov
em
ent
 
(SPI) fram
ew
o
rk
 to ensu
re reg
ulato
ry
 co
m
plian
ce fo
r th
e
 
softw
are dev
eloped in 
m
edical devices
.
 Th
e 
softw
are
 
fram
ew
o
rk
 introdu
ced h
ere (kn
o
w
n
 as M
edeSPI
 
–
 M
edical
 
D
evices
 Softw
are P
ro
cess
 Im
prov
em
ent)
 w
ill
 address
 an
 
oppo
rtu
nity
 to
 integ
rate th
e
 reg
ulato
ry
 issu
es and process 
im
prov
em
ent
 
m
ech
anism
s
 in
 o
rder to achiev
e
 im
prov
ed
 
softw
are
 p
ro
cesses.
 
 
 
 
1. Introduction. 
Softw
are is
 beco
m
ing
 an
 in
creasingly
 im
portant aspect 
of
 m
edical
 devices and m
edical device regulation
.
 M
edical
 
devices
 can
 o
nly
 be m
ark
eted
 if
 co
m
plian
ce and approv
al 
fro
m
 th
e appropriate reg
ulato
ry
 bodies
 of th
e F
o
od and
 
D
rug
 A
d
m
inistratio
n
 (FD
A)
 [1] (US
 requirem
ent), and th
e
 
Eu
ropean
 
C
o
m
m
issio
n
 
u
nder 
its
 
M
edical 
D
evice 
D
irectiv
es (M
DD) [2] (C
E 
m
arking
 
requirem
ent) is
 
achiev
ed.  
Integ
rated into th
e desig
n
 process
 of
 m
edical devices
,
 is 
th
e requirem
ent
 of
 th
e production
 and m
ainten
an
ce of
 a
 
device tech
nical file
,
 in
co
rporating a desig
n
 histo
ry
 file
.
 
 
D
esign
 histo
ry
 illustrates
 th
e
 
w
ell docum
ented, defin
ed
 
and controlled processes
 and outp
uts
,
 
u
ndertak
en
 in
 th
e
 
dev
elop
m
ent
 
of 
m
edical
 devices
 
and fo
r 
o
u
r
 particular
 
co
n
sid
eratio
n
 
w
ith
 
this
 
fram
ew
o
rk
 
-
 
th
e 
softw
a
re
 
co
m
pon
ents
.
 
M
any
 m
edical
 device m
an
ufactu
rers
,
 lik
e
 busin
esses
 in
 
m
o
st ind
u
stries, h
av
e
 b
ased
 
th
e
 
co
re 
of
 
th
eir q
u
ality
 
sy
stem
 o
n
 th
e ISO
9000:2000[3] fam
ily
 of
 standards
.
 
 Th
e 
intern
al
 qu
ality
 sy
stem
 of
 each
 m
edical device co
m
p
any
 
h
as
 
th
en
 
been
 
enh
an
ced 
to
 
en
su
re 
co
m
plian
ce 
w
ith
 
additio
n
al stand
ard
s th
at
 relate sp
ecifically
 to
 th
e n
atu
re of
 
th
eir 
produ
cts
 
and 
th
e 
m
ark
et 
th
ey
 
address
.
 
 
ISO
 
13485:2003, 
M
edical
 
devices
 
-
 Q
u
ality
 
m
an
ag
em
ent
 
sy
stem
s
 
-
 R
eq
uirem
ents
 fo
r 
reg
ulato
ry
 pu
rposes[4], fo
r 
in
stan
ce, 
is
 
based 
on
 
quality
 
m
an
ag
em
ent
 
sy
stem
 
requirem
ents
 
cu
rrently
 
co
ntain
ed 
in
 
m
edical 
device
 
reg
ulation
s
 
as
 
w
ell as
 
th
o
se 
appropriate requirem
ents
 
co
ntain
ed in
 ISO
 9001:2000.  
A
 recent 
study
 carried out
 by
 IQ Solutio
n
s
 
w
ith
 th
e
 
m
edical device co
m
p
anies
 in N
. Ireland h
as
 rev
ealed th
at
 
th
e softw
are
 dev
elop
m
ent
 process
 h
as been predom
in
ately 
based on
 th
e n
eed to co
m
ply
 w
ith
 th
e FD
A
 and Eu
ropean 
M
D
D
 regulatio
n
s.
 
 Th
e
 softw
are
 p
ro
cesses hav
e
 n
ot b
een
 
of
 prim
ary
 fo
cu
s
,
 o
nly
 th
at th
e elem
ents
 are in
 place th
at
 
satisfy
 th
e regulatory
 requirem
ents.   
It is
 believ
ed th
at 
a 
softw
are pro
cess
 im
prov
em
ent
 
ro
adm
ap w
hich
 in
co
rporates
 th
e g
o
als
 of
 m
edical device
 
softw
are
 fo
r
 m
eeting reg
ulato
ry
 co
m
plian
ce
 w
o
uld
 greatly
 
enh
an
ce th
e design
 co
ntrol procedu
res
 cu
rrently
 identified
 
w
ithin
 
co
m
p
any q
u
ality sy
stem
s.
 
 Q
u
ality softw
are
 is
 
d
efin
ed
 
as 
softw
are
 that 
m
eets its fu
n
ctio
n
al and
 
n
o
n
-
fu
n
ctio
n
al req
uirem
ents w
ith
o
ut lengthy
 rew
o
rk
,
 in
cluding
 
reg
ulato
ry
 
co
m
plian
ce, 
w
ith
o
ut 
any
 
in
co
n
sisten
cies.
 
 
R
ed
u
cing tim
e
 to
 
m
ark
et
 is
 
often
 b
ased
 
o
n
 
co
ntin
u
o
u
s
 
im
prov
em
ent
 
of processes
 im
plem
ented fo
r th
e desig
n
,
 
dev
elop
m
ent
 
and 
m
an
ufactu
re 
of
 
m
edical
 devices
 
and
 
produ
cts
.
 
In
 addition
,
 a recent su
rv
ey
 u
nd
ertak
en
 by
 th
e Centre 
fo
r Softw
are P
ro
cess
 T
ech
n
ologies
 (CSPT)
,
 indicated th
at
 
N
o
rthern
 
Ireland
 
health
 
technology
 
co
m
p
anies 
hav
e
 
lim
ited 
aw
aren
ess
 
of
 
standards
 
applied 
to
 
softw
are
 
dev
elop
m
ent, 
su
ch
 
as
 C
M
M
I
 [5].
 Th
e CSPT
 [6] is
 
a
 
research
 and kn
o
w
ledg
e
 transfer g
ro
up fu
nd
ed jointly
 by
 
th
e 
U
niv
ersity
 
of
 
U
lster
 
and 
a 
N
orth
ern
 
Ireland 
go
v
ern
m
ental o
rganisatio
n
 
ch
arged
 
w
ith
 
the
 
eco
n
o
m
ic
 
dev
elop
m
ent
 
of
 this
 g
eog
raphical
 
regio
n
.
 Th
e CSPT
 is
 
task
ed 
w
ith
 
m
otiv
ating
 
and 
supporting
 
a
 
cultu
re 
of
 
softw
are p
ro
cess im
p
ro
v
em
ent w
ithin
 th
e N
o
rth
ern
 Ireland
 
softw
are
 ind
u
stry
.
 Th
e
 
su
rv
ey
 findings noted
 th
at
 few
 
o
rg
anisation
s
 are aw
are of
 th
e
 co
n
cept of
 softw
are process
 
im
prov
em
ent
 
and 
m
o
re 
alarm
ingly
,
 
th
e im
portan
ce
 
of 
softw
are 
process
 
im
prov
em
ent 
fo
r 
in
creasing
 
m
ark
et
 
p
en
etratio
n
 w
o
rld
w
id
e, p
articularly
 in
 th
e U
.S.A
.
 
 If this is
 
n
ot addressed, m
edical device 
softw
are 
co
m
p
anies
 
w
ill
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experience difficulties in competing in markets where 
advanced software systems are required and time to 
market is crucial.   
Interestingly the prime factor here is not simply cost, 
but the quality agenda as a whole, with competitor 
companies possibly having already engaged in process 
improvement programs. Indeed, in countries such as China
[7] there is considerable recognition of the importance of 
quality in software development with the Chinese 
government not only setting up government agencies with 
responsibility for building the maturity of the Chinese 
software industry but also offering subsidies to software 
enterprises that engage in SPI based maturity evaluations. 
2. SPI framework. 
IQ Solutions and the CSPT are developing a software 
development framework for the medical device sector that 
addresses existing regulatory requirements for the control 
of the design, development, maintenance and support of 
software.  
The approach for delivering the software development 
framework is to establish a model (implemented as 
illustrated in Figure 1) that addresses the relevant 
regulations, and integrates those constraints within an SPI 
framework (i.e. MedeSPI). The model will be flexible in 
that relevant elements of the SPI framework may be 
adopted as required to provide the most significant benefit 
to the business.  For the purpose of this paper, the SPI 
framework used will be that of the CMMI [8] and the 
regulations used to extend the CMMI framework will be 
those of the FDA. 
3. Project outline. 
In order to deliver an endorsed framework it was 
essential that a steering group was formed with members 
from various medical device companies and a notified 
body with experience in auditing medical device 
companies.  The involvement of medical device 
companies also adds an ownership element to the model 
and should improve its acceptance and implementation 
within each company.   
The Software Development Method for Medical 
Devices (SDMMD) will be a defined set of software 
process models (in effect a methodology) which when 
utilised will meet the goals of MedeSPI. SDMMD will 
cover the complete lifecycle, defined by default, as the V-
Model in Figure 2.  No restriction will be made on the 
development lifecycle processes undertaken by individual 
companies, although it is understood that companies 
Extend the 
CMMI with 
new goals and 
practices
CMMI 
Regulatory 
bodies
MedeSPI
SDMMD:
Software Development 
Method for Medical 
Devices
Test in the medical 
device industry 
Figure 1: Software framework approach 
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within the medical device sector typically implement this 
V-Model.  In order to achieve this the project is divided 
into several stages. 
1. Assess the need for and commitment to the 
creation of SDMMD and MedeSPI 
2. Identify which parts of the CMMI are required to 
comply with FDA regulation and extend the 
CMMI with new goals and practices that are 
necessary to achieve FDA compliance (i.e. 
creation of MedeSPI). 
3. Develop process models for meeting the goals of 
MedeSPI (i.e.create SDMMD) 
4. Test SDMMD with Northern Ireland medical 
device companies 
Figure 2:  Software life cycle V model 
We have completed stage 1 of our work and are 
currently performing  stage 2 activities. 
4. MedeSPI development. 
SDMMD will provide a software development 
methodology, which addresses the regulatory guidance 
criteria, while introducing best processes that can be 
selected as required.   
MedeSPI will provide a means of assessing software 
engineering capability in twelve areas that have been 
defined by the FDA [9,10] as:   
1. Level of Concern 
2. Software Description 
3. Device Hazard and Risk Analysis 
4. Software Requirements Specification 
5. Architecture Design 
6. Design Specifications 
7. Requirements Traceability Analysis 
8. Development 
9. Validation, Verification and Testing [11]
10. Revision Level History 
11. Unresolved Anomalies 
12. Release Version Number 
MedeSPI is being developed to promote software 
process improvement practices into the software 
development processes of medical device companies. 
This is an attempt to improve the effectiveness and 
efficiency of software processes used by medical device 
companies through investigating the mapping between 
twelve CMMI process areas and the twelve FDA areas 
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listed above. The twelve CMMI process areas that we 
have deemed appropriate for the medical device industry 
are as follows: 
1. Project Planning, 
2. Project Monitoring & Control, 
3. Supplier Agreement Management, 
4. Risk Management, 
5. Requirements Management, 
6. Requirements Development, 
7. Technical Solution, 
8. Product Integration, 
9. Verification. 
10. Validation, 
11. Configuration Management, 
12. Process and Product Quality Assurance. 
The mappings between the FDA regulatory guidelines 
and the CMMI process areas listed above then produce 
twelve MedeSPI process areas which retain the CMMI 
process area names listed above. Each of the MedeSPI 
process areas will then be composed of a number of 
goals and practices. Goals and practices may be either 
generic (relating to the entire organisation) or specific 
(relating to the current process area).  MedeSPI 
investigates what parts of the CMMI process areas are 
required to satisfy FDA regulations, but also investigates 
the possibility of extending the CMMI process areas 
with additional goals and practices that are outside the 
remit of CMMI, but are required in order to satisfy FDA 
regulations The composition of the MedeSPI framework 
is illustrated in figure 3. 
 
A- CMMI Practices that are not mandatory for FDA 
compliance. 
B- CMMI Practices that are required for FDA 
compliance. 
C- Non-CMMI Practices that are required for FDA 
compliance. 
Figure 3. Composition of the MedeSPI framework. 
 
The model will help companies to measure their 
organisational capability and to track progression and 
achievements in each of the twelve process areas and 
against process capability levels.  The MedeSPI 
framework has adopted the following capability levels: 
• Level 0 – Companies must demonstrate that a 
process area satisfies the goals and performs the 
practices required to achieve FDA regulatory 
compliance. This will involve performing some 
practices which the CMMI views as generic, 
although not to the extent of fulfilling any generic 
goals. 
• Level 1 - Companies must demonstrate that a 
process area satisfies level 0 and the CMMI 
capability level 1 goal of performing the CMMI 
base practices. 
• Level 2 – Companies must demonstrate that a 
process area satisfies level 1 and additionally 
performs CMMI Advanced Practices, as well as the 
CMMI capability level 2 generic goal of 
Institutionalising a Managed Process. 
• Level 3 - Companies must demonstrate that a 
process area satisfies level 2 and additionally the 
CMMI Generic Goal to Institutionalise a Defined 
Process (CMMI Generic Goal 3). 
• Level 4 – Companies must demonstrate that a 
process area satisfies level 3 and additionally the 
CMMI Generic Goal to Institutionalise a 
Quantitatively Managed Process (CMMI Generic 
Goal 4). 
• Level 5 - Companies must demonstrate that a 
process area satisfies level 4 and additionally the 
CMMI Generic Goal to Institutionalise an 
Optimising Process (CMMI Generic Goal 5). 
What follows is a mapping of the FDA regulations to 
the CMMI for the Requirements Management (REQM) 
process area. This will demonstrate what CMMI goals 
and practices are required in order to satisfy FDA 
guidelines for requirements management. Software 
development within medical device companies could be 
improved by incorporating other CMMI practices that 
are not required to achieve FDA compliance. Comment 
is provided on how additional goals and practices (not 
included in the CMMI) may be added where necessary to 
satisfy FDA regulatory guidelines. REQM goals and 
practices have to be performed to satisfy each of the 
MedeSPI capability levels. 
6. Requirements management process area. 
FDA regulations [1] which have a counterpart within 
the goals and practices of the CMMI REQM process area 
A
B C
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and are related to the creation of software are identified.  
REQM has one specific goal which is SG1 Manage 
Requirements. In order that this goal is achieved it is 
necessary for the following five practices to be 
performed: 
1.1-1  Obtain an understanding of requirements, 
1.2-2  Obtain commitment to requirements, 
1.3-1  Manage requirements changes, 
1.4-2 Maintain bi-directional traceability of 
requirements, 
1.5-1 Identify inconsistencies between project 
work and requirements. 
Obtaining an understanding of requirements
involves several activities identified within CMMI as 
sub-practices. To fully perform 1.1-1, it is necessary to: 
• Establish criteria for distinguishing appropriate 
requirements providers, 
• Establish objective criteria for the acceptance of 
requirements, 
• Analyse requirements to ensure that the established 
criteria are met, 
• Reach an understanding of the requirements with the 
requirements provider so that the project participants 
can commit to them. 
The FDA regulations do not mandate any criteria for 
distinguishing providers of requirements. The formal 
identification of requirements providers is necessary to 
avoid conflict in the gathering of requirements from 
multiple and possibly unauthorised sources. This is a 
particular issue for software requirements because 
problems with requirements are very expensive to rectify 
later in a lifecycle. Although the FDA regulations 
recommend the creation of procedures to address 
incomplete and conflicting requirements, collecting 
requirements in parallel from different sources can 
exacerbate the problem. 
Establishing objective criteria for the acceptance of 
requirements suggests the need for potential 
requirements to be selected on the basis of agreed 
criteria. The FDA regulations do not require such criteria 
to be established. This is a fundamental issue during 
requirements gathering because of the need to weigh and 
prioritise the value of the software requirements to 
ensure only the incorporation of valid requirements into 
the software development process. The other side of the 
coin to establishing objective criteria is the inspection of 
the requirements to ensure compliance. Although there is 
a need to approve requirements within the FDA 
regulations, failure to stipulate a need for criteria, renders 
inspection against criteria impossible. There is a 
necessity to ensure that the design requirements relating 
to a device are appropriate and address the intended use 
of the device but alarmingly, within the FDA 
regulations, there is no specific necessity to reach an 
understanding of requirements with the requirements 
provider.   
Obtaining commitment to requirements (1.2-2), 
involves demonstrating that the following activities are 
being performed: 
• Assess the impact of requirements on existing 
commitments 
• Negotiate and record commitments 
There is no retrospective review of existing 
commitments recommended by the FDA regulations 
whenever new requirements are established and no 
treatment of the negotiating and recording of 
commitments. The ability of an organisation to create 
software which meets requirements is tied to its ability to 
handle its commitments. However, even the CMMI 
treats this as an advanced practice so perhaps it is not so 
surprising that the FDA regulations fail to address it. 
In managing requirements changes (1.3-1), an 
organisation needs to: 
• Capture all requirements and requirement changes 
that are given to or generated by the product, 
• Maintain the requirements change history with the 
rationale for the changes, 
• Evaluate the impact of requirements changes from 
the standpoint of relevant stakeholders, 
• Make the requirement and change data available to 
the project. 
The FDA regulations specifically require processes to 
ensure the completeness of requirements. However, 
changes to requirements are not specifically treated 
beyond the context of completeness. The FDA 
regulations do suggest that changes to documents or 
indeed any specification, shall follow a process and be 
reviewed and approved by an individual(s) in the same 
function or organization that performed the original 
review and approval, so at least in this respect, changes 
to requirements are indirectly recognised. 
Maintaining the requirements change history with the 
rationale for the changes is an issue strongly associated 
with configuration management. The FDA recommends 
the maintenance of a design history file where each 
manufacturer shall establish and maintain a history for 
each type of device. The history shall contain or 
reference the records necessary to demonstrate that the 
design was developed in accordance with the approved 
design plan and consequently, requirements. Further, the 
regulations mandate that each manufacturer shall 
maintain records of changes to documents including a 
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description of the change (presumably including 
requirements documents). This though should not be 
taken as reference to the maintenance of full and proper 
requirements configurations. When it is necessary to 
evaluate requirement changes from the standpoint of 
stakeholders, the regulations simply suggest a process 
should be followed for changes to specifications, no 
specific mention of stakeholders is made. Making 
requirement and change data available to the project has 
a counterpart in the FDA regulations where it suggests 
that documents shall be available at all locations for 
which they are designated, used, or otherwise necessary. 
Maintaining bi-directional traceability of 
requirements (1.4-2) involves: 
• Maintaining requirements traceability to ensure that 
the source of lower level requirements is 
documented, 
• Maintaining requirements traceability from a 
requirement to its derived requirements and to 
functions, objects, people, processes and work 
products, 
• Generating the requirements traceability matrix. 
With respect to traceability, the FDA regulations 
require that in certain circumstances procedures are 
established and maintained for identifying with a control 
number each unit, lot, or batch of finished devices and 
where appropriate components. This has an implicit 
reference to managing configurations and traceability but 
some would argue that there are many meanings to the 
word component and that taking this to imply 
requirements is a step too far. Again, the CMMI regards 
these practices as advanced. 
Identify inconsistencies between project work and 
requirements (1.5-1) is performed by: 
• Reviewing the projects plans, activities and work 
products for consistency with the requirements and 
the changes made to them, 
• Identifying the source of the inconsistency and the 
rationale, 
• Identifying changes that need to be made to the 
plans and work products resulting from changes to 
the requirements, 
• Initiating corrective action. 
The FDA regulations ensure during design 
verification that the design output meets the design input 
requirements. However, dealing with the source of the 
inconsistency, identifying changes to plans and initiating 
corrective action are ignored. 
The CMMI identifies a number of generic goals and 
practices. At a fundamental maturity or capability level it 
is only necessary to perform the specific base practices. 
It is interesting to note that FDA regulations with respect 
to REQM often have a counterpart in the CMMI. For 
REQM the generic goals and practices for capability 
level 2 are: 
GG 2: Institutionalise a Managed Process 
GP 2.1 Establish Policy 
GP 2.2 Plan the process 
GP 2.3 Provide Resources 
GP 2.4 Assign Responsibility 
GP 2.5 Train People 
GP 2.6 Manage Configurations 
GP 2.7 Identify stakeholders 
GP 2.8 M&C Process 
GP 2.9 Evaluate Adherence 
GP 2.10 Review
The FDA regulations state that each manufacturer 
shall establish the appropriate responsibility, authority, 
and interrelation of all personnel who manage, perform, 
and assess work affecting quality. It also undertakes to 
ensure that all work is adequately resourced and that 
staff are trained. 
The following table (Table 1) illustrates what REQM 
goals and practices have to be performed for each of the 
MedeSPI capability levels. 
Table 1: MedeSPI Requirements management process area components and capability levels
Goal Practice Sub-Practice Level 
SG1 Manage 
Requirements. 
1.1-1 Obtain an understanding of 
requirements 
Establish criteria for distinguishing appropriate 
requirements providers 
1 
SG1 Manage 
Requirements. 
1.1-1 Obtain an understanding of 
requirements 
Establish objective criteria for the acceptance of 
requirements 
1 
SG1 Manage 
Requirements. 
1.1-1 Obtain an understanding of 
requirements 
Analyse requirements to ensure that the established 
criteria are met 
1 
SG1 Manage 
Requirements. 
1.1-1 Obtain an understanding of 
requirements 
Reach an understanding of the requirements with the 
requirements provider so that the project participants 
can commit to them 
1 
SG1 Manage 1.2-2 Obtain commitment to Assess the impact of requirements on existing 2 
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Requirements. requirements commitments 
SG1 Manage 
Requirements. 
1.2-2 Obtain commitment to 
requirements 
Negotiate and record commitments 2 
SG1 Manage 
Requirements 
1.3-1 Manage requirements 
changes 
Capture all requirements and requirement changes that 
are given to or generated by the product 
0 
SG1 Manage 
Requirements 
1.3-1 Manage requirements 
changes 
Maintain the requirements change history with the 
rationale for the changes 
0 
SG1 Manage 
Requirements 
1.3-1 Manage requirements 
changes 
Evaluate the impact of requirements changes from the 
standpoint of relevant stakeholders 
1 
SG1 Manage 
Requirements 
1.3-1 Manage requirements 
changes 
Make the requirement and change data available to the 
project. 
0 
SG1 Manage 
Requirements 
1.4-2. Maintain bi-directional 
traceability of requirements 
Maintaining requirements traceability to ensure that the 
source of lower level requirements is documented 
1 
SG1 Manage 
Requirements 
1.4-2. Maintain bi-directional 
traceability of requirements 
Maintaining requirements traceability from a 
requirement to its derived requirements and to 
functions, objects, people, processes and work products 
0 
SG1 Manage 
Requirements 
1.4-2. Maintain bi-directional 
traceability of requirements 
Generating the requirements traceability matrix 2 
SG1 Manage 
Requirements 
1.5-1 Identify inconsistencies 
between project work and 
requirements. 
Reviewing the projects plans, activities and work 
products for consistency with the requirements and the 
changes made to them 
0 
SG1 Manage 
Requirements 
1.5-1 Identify inconsistencies 
between project work and 
requirements. 
Identifying the source of the inconsistency and the 
rationale 
1 
SG1 Manage 
Requirements 
1.5-1 Identify inconsistencies 
between project work and 
requirements. 
Identifying changes that need to be made to the plans 
and work products resulting from changers to the 
requirements 
1 
SG1 Manage 
Requirements 
1.5-1 Identify inconsistencies 
between project work and 
requirements. 
Initiating corrective action 1 
GG 2:Institutionalise 
a Managed Process 
(IMP) 
GP 2.1 Establish Policy 
 
 2 
GG 2:IMP 
 
 
GP 2.2 Plan the process  2 
GG 2:IMP GP 2.3 Provide Resources  0 
GG 2:IMP GP 2.4 Assign Responsibility  0 
GG 2:IMP GP 2.5 Train People  0 
GG 2:IMP GP 2.6 Manage Configurations  2 
GG 2:IMP GP 2.7 Identify stakeholders  2 
GG 2:IMP GP 2.8 M&C Process  2 
GG 2:IMP GP 2.9 Evaluate Adherence  2 
GG 2:IMP GP 2.10 Review  2 
GG3 :Institutionalise 
a Defined Process  
GP 3.1 Establish a defined Process  3 
GG3 :Institutionalise 
a Defined Process 
GP 3.2 Collect Improvement 
Information 
 3 
GG4 :Institutionalise 
a Quantitatively 
Managed Process  
GP 4.1 Establish Quantitative 
Objectives for the Process 
 4 
GG4 :Institutionalise 
a Quantitatively 
Managed Process 
GP 4.2 Stabilise Sub-process 
Performance 
 4 
GG5 :Institutionalise 
an Optimising 
Process 
GP 5.1 Ensure Continuous Process 
Improvement  
 5 
GG5 Institutionalise 
an Optimising 
Process 
GP 5.2 Correct Root Causes of 
Problems 
 5 
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7. Conclusion. 
With respect then to the specific goals and practices of 
the requirements management process area, it is clear that 
following FDA regulations will only, at best, partially 
meet the goals of this CMMI process area. As might 
reasonably be expected, there is no support within the 
FDA regulations for the advanced practices of 
requirements management but perhaps more surprising 
there is little equality between more fundamental practices 
of requirements management and those mandated in the 
FDA regulations. It is difficult to come to terms with 
regulations which permit compliance for requirements 
management practices which do not cater for identifying 
formally a source of requirements nor for the formal 
assessment of requirements.  Requirements are the 
fundamental starting point for the birth of a software 
system and their full and proper understanding is essential 
for efficient and effective software development. 
Since failure to perform any specific practice implies 
failure to meet the specific goal, with respect to CMMI, it 
is clear, the goals of REQM cannot be obtained by 
satisfying FDA regulations during software development. 
But is the opposite true, can meeting the CMMI goals for 
REQM successfully meet FDA regulations? Certainly for 
REQM, meeting the goals of the process area by 
performing the specific practices more than meets the 
FDA regulations in this area. For REQM, the existing 
CMMI specification of goals and practices can be carried 
over, without extension into the MedeSPI framework. 
Our work continues for stage 2 of our project. We will 
endeavour to examine all of the appropriate process areas 
within the CMMI referred to in the FDA regulations, 
investigating the extent to which the CMMI framework 
needs to be extended to create MedeSPI.  
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